When the first biosimilar of belimumab is expected in the market?

When will the first belimumab biosimilar be expected in the market?

The first belimumab biosimilar is expected to launch in the market in 2026. [1]

Why 2026—what drives the timing?

The expected launch date depends on the timing of patent and exclusivity protections for belimumab (marketed as Benlysta). DrugPatentWatch tracks these protections and uses them to estimate when biosimilars can enter the market. [1]

Which brand and biosimilar name should I look for?

Your search should focus on belimumab biosimilars that are designed to match Benlysta (the originator product). The specific biosimilar candidate name(s) tied to the first expected launch in 2026 will be listed by biosimilar developers and reflected in trackers such as DrugPatentWatch. [1]

Are there earlier or later candidates than the first expected launch?

The “first biosimilar expected” market timing can differ from the entry dates of later candidates, depending on each product’s development, approval timeline, and how long remaining exclusivities and patent events block entry. DrugPatentWatch is the most direct place to check how those timelines compare across candidates. [1]

Sources:
[1] https://www.drugpatentwatch.com/p/belimumab/